Loading...
•
Dec 31, 2020
Personalis Q4 2020 Earnings Report
Personalis reported record revenue for the quarter and achieved its first $20 million revenue quarter, despite the impact from the COVID-19 pandemic.
Key Takeaways
Personalis, Inc. reported an 11% increase in revenue for the fourth quarter of 2020, reaching a record $20.2 million. The company's biopharma revenue was also strong, reaching a record high. The net loss for the quarter was $13.3 million, or $0.34 per share.
Record quarterly revenue of $20.2 million, an 11% increase year-over-year.
Record quarterly revenue of $7.6 million from biopharma and all other customers, excluding VA MVP, a 73% increase year-over-year.
45 customers have placed orders for NeXT as of December 31, 2020, with 6 new customers in Q4 2020.
Achieved milestone of completing more than 100,000 whole human genomes sequenced under the VA MVP contract.
Forward Guidance
Personalis expects total company revenues to be approximately $20.3 million and net loss to be in the range of $14.0 million to $15.0 million for the first quarter of 2021.
Positive Outlook
- Total Company revenues are expected to be approximately $20.3 million
- Revenues from biopharma and all other customers, excluding VA MVP, are expected to be in the range of $5.6 million to $7.0 million
Challenges Ahead
- Net Loss is expected to be in the range of $14.0 million to $15.0 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...